TY - JOUR
T1 - Risk of choroidal neovascularization among the uveitides
AU - Baxter, Sally L.
AU - Pistilli, Maxwell
AU - Pujari, Siddharth S.
AU - Liesegang, Teresa L.
AU - Suhler, Eric B.
AU - Thorne, Jennifer E.
AU - Foster, C. Stephen
AU - Jabs, Douglas A.
AU - Levy-Clarke, Grace A.
AU - Nussenblatt, Robert B.
AU - Rosenbaum, James T.
AU - Kempen, John H.
N1 - Funding Information:
All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest and the following were reported. Jennifer E. Thorne serves a consultant for Allergan and XOMA. C. Stephen Foster serves as a lecturer for Alcon, Inspire, Ista, and Centocor; as a Consultant for Sirion; as a consultant and lecturer for Allergan and Bausch & Lomb; and as an equity owner for EyeGate. Douglas A. Jabs serves a consultant for Abbott Laboratories, Alcon Laboratories, Allergan Pharmaceutical Corporation, Corcept Therapeutics, Genentech, Genzyme Corporation, GlaxoSmith Kline, and Roche Pharmaceuticals and is a member of the Data and Safety Monitoring Board for Applied Genetic Technologies Corporation and Novartis Pharmaceutical Corporation. Grace A. Levy-Clarke is employed by Johnson & Johnson Vision Care. James T. Rosenbaum serves or has served as a consultant for Abbott Laboratories, Amgen, Allergan, Genentech, Novartis, and UCB and has been involved in clinical trials for Abbott Laboratories, Genentech, Lux Biosciences, and Eyegate Pharma. John H. Kempen serves or has served as a consultant for Alcon, Allergan, Can-Fite, Clearside, Lux Biosciences, Sanofi-Pasteur, and Xoma. Supported primarily by Grant EY014943 from the National Eye Institute , National Institutes of Health , Bethesda, Maryland (J.H.K.). Additional support was provided by Research to Prevent Blindness, Inc, New York, New York, and the Paul and Evanina Mackall Foundation. Dr Kempen was a Research to Prevent Blindness James S Adams Special Scholar Award recipient, Dr Thorne was a Research to Prevent Blindness Harrington Special Scholar Award recipient, and Drs Jabs and Rosenbaum were Research to Prevent Blindness Senior Scientific Investigator Award recipients during the course of the study. Dr Levy-Clarke was previously supported by and Dr Nussenblatt continues to be supported by intramural funds from the National Eye Institute. Dr Suhler receives support from the Department of Veterans' Affairs. None of the sponsors had any role in the design and conduct of the report; collection, management, analysis, and interpretation of the data; or in the preparation, review, and approval of this manuscript. Involved in Design and conduct of study (S.L.B., M.P., J.H.K.); Collection, management, analysis, and interpretation of data (all authors); Preparation of manuscript (S.L.B., M.P., J.H.K.); and review and approval of manuscript (all authors).
PY - 2013/9
Y1 - 2013/9
N2 - Purpose: To evaluate the risk, risk factors, and visual impact of choroidal neovascularization (CNV) in uveitis cases. Design: Retrospective cohort study. Methods: Standardized medical record review at 5 tertiary centers. Results: Among 15 137 uveitic eyes (8868 patients), CNV was rare in the cases of anterior or intermediate uveitis. Among the 4041 eyes (2307 patients) with posterior uveitis or panuveitis, 81 (2.0%) had CNV at presentation. Risk factors included posterior uveitis in general and specific uveitis syndromes affecting the outer retina-retinal pigment epithelium-choroid interface. Among the 2364 eyes (1357 patients) with posterior uveitis or panuveitis and free of CNV at the time of cohort entry, the cumulative 2-year incidence of CNV was 2.7% (95% confidence interval [CI], 1.8% to 3.5%). Risk factors for incident CNV included currently active inflammation (adjusted hazard ratio [aHR], 2.13; 95% CI, 1.26 to 3.60), preretinal neovascularization (aHR, 3.19; 95% CI, 1.30 to 7.80), and prior diagnosis of CNV in the contralateral eye (aHR, 5.79; 95% CI, 2.77 to 12.09). Among specific syndromes, the incidence was greater in Vogt-Koyanagi-Harada syndrome (aHR, 3.37; 95% CI, 1.52 to 7.46) and punctate inner choroiditis (aHR, 8.67; 95% CI, 2.83 to 26.54). Incident CNV was associated with a 2-line loss of visual acuity (+0.19 logarithm of the minimal angle of resolution units; 95% CI, 0.079 to 0.29) from the preceding visit. Conclusions: CNV is an uncommon complication of uveitis associated with visual impairment that occurs more commonly in forms affecting the outer retina-retinal pigment epithelium-choroid interface, during periods of inflammatory activity, in association with preretinal neovascularization, and in second eyes of patients with unilateral CNV. Because CNV is treatable, a systematic approach to early detection in high-risk patients may be appropriate.
AB - Purpose: To evaluate the risk, risk factors, and visual impact of choroidal neovascularization (CNV) in uveitis cases. Design: Retrospective cohort study. Methods: Standardized medical record review at 5 tertiary centers. Results: Among 15 137 uveitic eyes (8868 patients), CNV was rare in the cases of anterior or intermediate uveitis. Among the 4041 eyes (2307 patients) with posterior uveitis or panuveitis, 81 (2.0%) had CNV at presentation. Risk factors included posterior uveitis in general and specific uveitis syndromes affecting the outer retina-retinal pigment epithelium-choroid interface. Among the 2364 eyes (1357 patients) with posterior uveitis or panuveitis and free of CNV at the time of cohort entry, the cumulative 2-year incidence of CNV was 2.7% (95% confidence interval [CI], 1.8% to 3.5%). Risk factors for incident CNV included currently active inflammation (adjusted hazard ratio [aHR], 2.13; 95% CI, 1.26 to 3.60), preretinal neovascularization (aHR, 3.19; 95% CI, 1.30 to 7.80), and prior diagnosis of CNV in the contralateral eye (aHR, 5.79; 95% CI, 2.77 to 12.09). Among specific syndromes, the incidence was greater in Vogt-Koyanagi-Harada syndrome (aHR, 3.37; 95% CI, 1.52 to 7.46) and punctate inner choroiditis (aHR, 8.67; 95% CI, 2.83 to 26.54). Incident CNV was associated with a 2-line loss of visual acuity (+0.19 logarithm of the minimal angle of resolution units; 95% CI, 0.079 to 0.29) from the preceding visit. Conclusions: CNV is an uncommon complication of uveitis associated with visual impairment that occurs more commonly in forms affecting the outer retina-retinal pigment epithelium-choroid interface, during periods of inflammatory activity, in association with preretinal neovascularization, and in second eyes of patients with unilateral CNV. Because CNV is treatable, a systematic approach to early detection in high-risk patients may be appropriate.
UR - http://www.scopus.com/inward/record.url?scp=84882259786&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2013.04.040
DO - 10.1016/j.ajo.2013.04.040
M3 - Article
AN - SCOPUS:84882259786
SN - 0002-9394
VL - 156
SP - 468-477.e2
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
IS - 3
ER -